AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.560
+0.110 (4.49%)
At close: Jun 26, 2026, 4:00 PM EDT
2.580
+0.020 (0.78%)
After-hours: Jun 26, 2026, 4:27 PM EDT
AC Immune Revenue
AC Immune had revenue of 1.12M CHF in the quarter ending March 31, 2026, with 13.03% growth. This brings the company's revenue in the last twelve months to 3.70M, down -86.92% year-over-year. In the year 2025, AC Immune had annual revenue of 3.57M, down -86.92%.
Revenue (ttm)
3.70M CHF
Revenue Growth
-86.92%
P/S Ratio
55.02
Revenue / Employee
30,344 CHF
Employees
122
Market Cap
253.95M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | -23.74M | -86.92% |
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.54M | 1,498.03% |
| Dec 31, 2018 | 6.91M | -13.34M | -65.88% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Fulcrum Therapeutics | 80.00M |
| Invivyd | 55.87M |
| Orchestra BioMed Holdings | 32.72M |
| Foghorn Therapeutics | 28.22M |
| Sol-Gel Technologies | 18.47M |
| Fate Therapeutics | 6.32M |
| Armata Pharmaceuticals | 5.20M |
ACIU News
- 17 days ago - AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease - GlobeNewsWire
- 23 days ago - AC Immune Slides: Investor presentation - Filings
- 5 weeks ago - AC Immune presents new Phase 1 data on uptake of ACI-19626 - TheFly
- 5 weeks ago - AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS - GlobeNewsWire
- 6 weeks ago - Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care - GlobeNewsWire
- 6 weeks ago - AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM - GlobeNewsWire
- 2 months ago - AC Immune reports Q1 EPS (15c), consensus (14c) - TheFly
- 2 months ago - AC Immune First Quarter 2026 Financial and Corporate Updates - GlobeNewsWire